-
-
-
-
-
-
-
Kiora Pharmaceuticals posts net income in Q3 amid ongoing clinical trials
-
-
-
-
-
-
-
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
-
-
-
-
-
-
-
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
-
-
-
-
-
-
-
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
-
-
-
-
-
-
-
Kiora Pharmaceuticals (KPRX) Misses Q2 EPS by 53c
-
-
-
-
-
-
-
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

